GSE239844 crizotinib 4 v 5 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE239844_crizotinib_4_v_5_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE239844_crizotinib_4_v_5_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE239844_crizotinib_4_v_5_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE239844_crizotinib_4_v_5_human_up.

Results found

Linked to

 

Label

Description

 

Gene

CASTOR family member 3, pseudogene

Gene

MIR1915 host gene

Gene

PSMG3 antisense RNA 1

Gene

transmembrane protein 198B (pseudogene)

Gene

zinc finger domain-containing protein LOC728743

Gene

STARD4 antisense RNA 1

Gene

mir-99a-let-7c cluster host gene

Gene

general transcription factor IIi pseudogene 1

Gene

long intergenic non-protein coding RNA 1133

Gene

ALDH1A3 antisense RNA 1

  • Gene

    CASTOR family member 3, pseudogene



  • Gene

    PSMG3 antisense RNA 1


  • Gene

    transmembrane protein 198B (pseudogene)


  • Gene

    zinc finger domain-containing protein LOC728743


  • Gene

    STARD4 antisense RNA 1


  • Gene

    mir-99a-let-7c cluster host gene


  • Gene

    general transcription factor IIi pseudogene 1


  • Gene

    long intergenic non-protein coding RNA 1133


  • Gene

    ALDH1A3 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.